(PDF) FKB327, an Adalimumab Biosimilar, Versus the

FKB327, an Adalimumab Biosimilar, Versus the Reference Product: Results of a Randomized, Phase III, Double-Blind Study, and Its Open-Label Extension

Arthritis Research & Therapy

doi 10.1186/s13075-019-2046-0

Full Text

Open PDF

Abstract

Available in full text

Date

December 1, 2019

Authors

Elias Chalouhi El Khouri

Publisher

Springer Science and Business Media LLC

Related search

OP0021 Efficacy and Safety Results of a Phase Iii Study Comparing Fkb327, an Adalimumab Biosimilar, With the Adalimumab Reference Product in Patients With Active Rheumatoid Arthritis

2017

English

Adalimumab for Nail Psoriasis: Efficacy and Safety From the Open-Label Extension of a Phase-3, Randomized, Placebo-Controlled Trial

SKIN The Journal of Cutaneous Medicine

2017

English

Comparative Evaluation of the Long-Term Efficacy and Safety of the Infliximab Biosimilar BCD-055 and Reference Infliximab in Patients With Ankylosing Spondylitis: Results of the International Multicenter Randomized Double-Blind Phase Iii Clinical Study Asart-2

Nauchno-Prakticheskaya Revmatologiya

English

Switch From Reference Etanercept to SDZ ETN, an Etanercept Biosimilar, Does Not Impact Efficacy, Safety, and Immunogenicity of Etanercept in Patients With Moderate-To-Severe Rheumatoid Arthritis: 48-Week Results From the Phase III, Randomized, Double-Blind EQUIRA Study

Arthritis Research & Therapy

2019

English

Over-The-Counter Nicotine Patch Therapy for Smoking Cessation: Results From Randomized, Double-Blind, Placebo-Controlled, and Open Label Trials.

American Journal of Public Health

English

Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Chronic Plaque Psoriasis: Long-Term Efficacy and Safety Results From 2 Randomized Phase-Iii Studies and 1 Open-Label Long-Term Extension Study

Journal of the American Academy of Dermatology

Dermatology

2016

English

BP-C1 in Treatment of Patients With Stage IV Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study and Additional Open-Label Treatment Phase.

Journal of Clinical Oncology

English

AB0954 a Randomised, Double-Blind Trial Comparing the Efficacy, Safety and Immunogenicity of Msb11022, a Proposed Biosimilar of Adalimumab, Versus Adalimumab Originator in Patients With Moderate-To-Severe Plaque Psoriasis

2018

English

Erratum To: Pasireotide LAR Maintains Inhibition of GH and IGF-1 in Patients With Acromegaly for Up to 25 Months: Results From the Blinded Extension Phase of a Randomized, Double-Blind, Multicenter, Phase III Study

English

Amanote Research

FKB327, an Adalimumab Biosimilar, Versus the Reference Product: Results of a Randomized, Phase III, Double-Blind Study, and Its Open-Label Extension

Arthritis Research & Therapy

doi 10.1186/s13075-019-2046-0

Full Text

Abstract

Date

Authors

Publisher

Related search

OP0021 Efficacy and Safety Results of a Phase Iii Study Comparing Fkb327, an Adalimumab Biosimilar, With the Adalimumab Reference Product in Patients With Active Rheumatoid Arthritis

Adalimumab for Nail Psoriasis: Efficacy and Safety From the Open-Label Extension of a Phase-3, Randomized, Placebo-Controlled Trial

Comparative Evaluation of the Long-Term Efficacy and Safety of the Infliximab Biosimilar BCD-055 and Reference Infliximab in Patients With Ankylosing Spondylitis: Results of the International Multicenter Randomized Double-Blind Phase Iii Clinical Study Asart-2

Switch From Reference Etanercept to SDZ ETN, an Etanercept Biosimilar, Does Not Impact Efficacy, Safety, and Immunogenicity of Etanercept in Patients With Moderate-To-Severe Rheumatoid Arthritis: 48-Week Results From the Phase III, Randomized, Double-Blind EQUIRA Study

Over-The-Counter Nicotine Patch Therapy for Smoking Cessation: Results From Randomized, Double-Blind, Placebo-Controlled, and Open Label Trials.

Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Chronic Plaque Psoriasis: Long-Term Efficacy and Safety Results From 2 Randomized Phase-Iii Studies and 1 Open-Label Long-Term Extension Study

BP-C1 in Treatment of Patients With Stage IV Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study and Additional Open-Label Treatment Phase.

AB0954 a Randomised, Double-Blind Trial Comparing the Efficacy, Safety and Immunogenicity of Msb11022, a Proposed Biosimilar of Adalimumab, Versus Adalimumab Originator in Patients With Moderate-To-Severe Plaque Psoriasis

Erratum To: Pasireotide LAR Maintains Inhibition of GH and IGF-1 in Patients With Acromegaly for Up to 25 Months: Results From the Blinded Extension Phase of a Randomized, Double-Blind, Multicenter, Phase III Study